Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-specific neoantigen peptide-HLA complexes are formed when mutated peptides derived from tumor cells are presented on the cell surface by human leukocyte antigen (HLA) molecules. These complexes serve as targets for T cell recognition and cancer immunotherapy. They play a crucial role in signaling the presence of cancerous cells to the immune system, leading to T cell activation and tumor rejection. Targeting these complexes is a promising avenue for personalized cancer immunotherapy.
Presentation of tumor-specific mutated peptides to T cells, leading to T cell activation and tumor cell lysis.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-specific Neoantigen Peptide-HLA Complex (pHLA).